Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
Daniel S.W. Tan, Natasha B. Leighl, Gregory J. Riely, James Chih‐Hsin Yang, Lecia V. Sequist, Juergen Wolf, Takashi Seto, Enriqueta Felip, Santiago Ponce Aix, Maud Jonnaert, Chun Pan, Eugene Y. Tan, Jinnie Ko, Susan E. Moody, Dong‐Wan Kim
Topics & Concepts
MedicineOncologyOpen labelInternal medicineLungPhases of clinical researchSmall Cell Lung CarcinomaCarcinomaMutantSmall-cell carcinomaClinical trialGeneticsGeneBiologyLung Cancer Treatments and MutationsChronic Myeloid Leukemia TreatmentsInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis